Stay updated on Avadomide and Nivolumab Combo in Adv Melanoma Clinical Trial
Sign up to get notified when there's something new on the Avadomide and Nivolumab Combo in Adv Melanoma Clinical Trial page.

Latest updates to the Avadomide and Nivolumab Combo in Adv Melanoma Clinical Trial page
- ChecktodayChange DetectedThe footer’s site revision number changed from v3.7.2 to v3.8.0; the study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe footer revision marker changes from v3.7.1 to v3.7.2 while the page remains a 403 error page.SummaryDifference0.2%

- Check21 days agoChange DetectedThe footer's ClinicalTrials.gov revision label changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check42 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the detailed study record with only a minimal header and a Home link. The core content such as the title, summary, eligibility criteria, and outcomes is no longer accessible.SummaryDifference18%

- Check49 days agoChange DetectedThe page's revision tag was updated from v3.6.6 to v3.7.0, signaling a site update while preserving the displayed study information.SummaryDifference0.1%

- Check56 days agoChange DetectedDeleted the MedlinePlus related topics header and its entries for Melanoma and MedlinePlus Genetics from the page, removing quick-access links to these related topics.SummaryDifference0.2%

Stay in the know with updates to Avadomide and Nivolumab Combo in Adv Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avadomide and Nivolumab Combo in Adv Melanoma Clinical Trial page.